Skip to main content

Viatris Inc Value Stock - Dividend - Research Selection

Viatris

ISIN: US92556V1061 , WKN: A2QAME

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


2025 Performance Review And Future Strategy

2025-12-22
Discover top biotech stock picks for 2025 with strong growth potential and overlooked catalysts.

Viatris: Looks Cheap, But Faces Continued Contraction

2025-12-22
Viatris faces revenue declines, execution issues, and high debt post-merger. Click here to read my latest analysis of VTRS stock.

Is Viatris’ Shift Into Complex Therapies Altering The Investment Case For VTRS?

2025-12-20
Earlier this week, Viatris announced four pipeline milestones, including US FDA approval of its generic version of Sandostatin LAR Depot and regulatory progress on a low-dose contraceptive patch, an ophthalmology candidate for neurotrophic keratopathy, and pitolisant for obstructive sleep apnea in Japan. These advances highlight Viatris’ push into complex injectables, transdermal contraception, and specialty treatments, broadening its portfolio beyond traditional, lower-margin...

Viatris (VTRS): Reassessing Valuation After Recent Share Price Gains and Evolving Investor Sentiment

2025-12-20
Viatris stock moves and what is driving sentiment Viatris (VTRS) has quietly climbed about 14% over the past month and roughly 21% in the past 3 months, even though the share price is still slightly negative year to date. See our latest analysis for Viatris. Zooming out, that recent 1 month share price return of around 14% and a roughly 21% gain over 3 months stands in contrast to a still negative year to date share price return. This suggests sentiment has only recently started to turn as...

1 S&P 500 Stock with Impressive Fundamentals and 2 That Underwhelm

2025-12-19
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials

2025-12-18
Viatris (VTRS) said Thursday the US Food and Drug Administration approved octreotide acetate for inj

Viatris Provides Pipeline Update on Four Regulatory Milestones

2025-12-18
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced four recent regulatory milestones spanning across all stages of its global pipeline:

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-17
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 2026. The Company's presentation and fireside chat will begin at 9 a.m. PT / 12 p.m. ET.

Does Viatris’ Reshaping Strategy Make Sense After Recent Share Price Swings?

2025-12-16
If you are wondering whether Viatris is quietly undervalued or just a value trap in disguise, you are in the right place and we will unpack what the current price is really telling us. The stock has been choppy, with a 4.2% gain over the last week and 8.8% over the past month, but it is still down 6.1% year to date and 2.7% over the last year. This suggests that sentiment is still catching up with the fundamentals. Recent attention around Viatris has focused on its ongoing portfolio...

Is Viatris Stock Outperforming the Dow?

2025-12-15
As Viatris has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.